Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19). Academic Article uri icon

Overview

abstract

  • INTRODUCTION: SARS-CoV-2, the virus that causes COVID-19, elicits a variety of host responses ranging from asymptomatic or mild illness in most people, to severe disease and critical illness in a subset of patients with systemic inflammation and hypoxemic respiratory failure. AREAS COVERED: Heterogeneous clinical presentations are often driven by disparate responses of the host immune system, with severe disease associated with aberrant interferon signaling or cytokine storm syndrome. This manuscript examines current therapeutic approaches, including the use of immunomodulators such as corticosteroids, interleukin inhibitors, kinase inhibitors, fluvoxamine, and ivermectin, and also explores the ways that these therapies and others may be used to treat COVID-19 in the future. EXPERT OPINION: Modulation of the immune response has become a mainstay of treatment of COVID-19, although the optimal mechanism has not yet been defined and there is considerable controversy regarding clinical management. As time progresses, the therapeutic approach to COVID-19 will undoubtedly change, particularly as we learn more about the pathophysiology of SARS-CoV-2 infection.

publication date

  • February 1, 2022

Research

keywords

  • COVID-19 Drug Treatment

Identity

PubMed Central ID

  • PMC8862166

Scopus Document Identifier

  • 85124241388

Digital Object Identifier (DOI)

  • 10.1080/14656566.2022.2035360

PubMed ID

  • 35103549

Additional Document Info

volume

  • 23

issue

  • 5